Drug repositioning: identifying and developing new uses for existing drugs

@article{Ashburn2004DrugRI,
  title={Drug repositioning: identifying and developing new uses for existing drugs},
  author={Ted T. Ashburn and Karl B. Thor},
  journal={Nature Reviews Drug Discovery},
  year={2004},
  volume={3},
  pages={673-683}
}
Biopharmaceutical companies attempting to increase productivity through novel discovery technologies have fallen short of achieving the desired results. Repositioning existing drugs for new indications could deliver the productivity increases that the industry needs while shifting the locus of production to biotechnology companies. More and more companies are scanning the existing pharmacopoeia for repositioning candidates, and the number of repositioning success stories is increasing. 
Drug Repositioning: A Faster Path to Drug Discovery
TLDR
Successfully repositioned drugs such as Viagra have hit the market with exponential pharmaceutical revenue records made at a fraction of the cost versus de novo methodologies paving the way for drug prospects that follow in similar footsteps.
Drug Repositioning : Old Drugs For New Indications
TLDR
The process of finding new uses of existing drugs outside the scope of the original indication is known as drug repositioning, which is less costly, less time consuming and relatively safe method.
Mining small-molecule screens to repurpose drugs
TLDR
It is hopeful that high-throughput screens of small molecules will accelerate the discovery of new uses for known drugs, but this hope has not yet been realized.
Drug repositioning by structure-based virtual screening.
TLDR
The basic principles and recent advances in structure-based virtual screening are outlined and the powerful synergy of in silico techniques in drug repositioning as demonstrated in several recent reports are highlighted.
Computational Drug Repositioning: Current Progress and Challenges
TLDR
This review introduces publicly available databases for drug repositioning and summarizes the approaches taken and highlights and compares their characteristics and challenges, which should be addressed for the future realization of drugRepositioning.
New drugs are not enough-drug repositioning in oncology: An update
TLDR
The present review summarizes the most prominent examples of drug repositioning for the treatment of cancer, taking into consideration their primary use, proposed anticancer mechanisms and current development status.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 67 REFERENCES
A guide to drug discovery: Trends in development and approval times for new therapeutics in the United States
The process of clinical development and regulatory review of new therapeutics in the United States was significantly changed by a number of legislative acts passed in the 1980s and 1990s. These acts
New ways to take old drugs.
TLDR
People taking AZT and ritonavir can sometimes switch to a product called Combivir, a combination of the two, and Saquinavir patients may be able to switched to a gel formulation of the same drug, Fortovase, that is more readily absorbed by the body.
Colonizing therapeutic space: the overlooked science of drug husbandry
  • Biology
    Nature Reviews Drug Discovery
  • 2004
An ever-increasing emphasis on the power of applying new technology to the early stages of drug discovery might be obscuring the role that clinical science has to play in increasing the number of
Rebuilding Big Pharma ’ s Business Model
The blockbuster business model that underpinned Big Pharma's success is now irreparably broken. The industry needs a new approach. I While the business climate for pharma companies has changed
Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy.
TLDR
It should soon prove possible to block polyamine biosynthesis at every step in the pathway, and this approach will enable a full examination of the potential of this approach.
Dark Remedy: The Impact of Thalidomide and Its Revival as a Vital Medicine
TLDR
The author uses his scientific and literary skills in an ambitious attempt to target both a lay and scientific audience in describing the inside story of how the authors came to sequence the human genome and the significance of this endeavor.
Polyamine metabolism: a potential therapeutic target in trypanosomes.
TLDR
alpha-Difluoromethylornithine (RMI 71,782), a specific irreversible inhibitor of the first step in polyamine biosynthesis, cures mice infected with a virulent, rodent-passaged strain of Trypanosoma brucei bruceo, drawing attention to polyamine metabolism as a target for chemotherapy of parasitic diseases.
Thalidomide is an inhibitor of angiogenesis.
TLDR
Electron microscopic examination of the corneal neovascularization of thalidomide-treated rabbits revealed specific ultrastructural changes similar to those seen in the deformed limb bud vasculature ofThalidomid-treated embryos, which shed light on the mechanism of the teratogenicity of the drug.
Moving beyond the genome projects
Does the future of genomics-based drug discovery lie with the mouse?
Dark Remedy: The Impact of Thalidomide and Its Revival as a Vital Medicine
TLDR
A parable about compassion-and the absence of it-Dark Remedy is a gripping account of thalidomide's extraordinary impact on the lives of individuals and nations over half a century.
...
1
2
3
4
5
...